HiT-GlyP

Important results from the project

The Hit-GlyP consortium aimed at developing the world´s first system for targeted and reliable protein glycosylation to streamline the discovery and production of protein-based drugs. The goal was to create a platform that could evaluate and produce protein-based drugs with all types of glycosylation in a faster and more cost-effective way, which would open new avenues for future drug development.

Expected long term effects

During the HiT-GlyP project, EnginZyme expanded its EziG immobilization technology for industrial applications, opening up new use areas. When solubility problems arose with certain glycosylation enzymes, all project partners jointly focused on finding solutions. EnginZyme contributed by creating new enzyme variants for Wageningen Universitet. Despite progress, the delays led to EnginZyme choosing to leave HiT-GlyP. EnginZyme is still confident that its project partners will resolve these issues going forward.

Approach and implementation

The Hit-GlyP consortium consisted of: Leniobio specialized in protein expression; Wageningen University (WUR) research on glucosylation enzymes; EnginZyme with its general enzyme immobilization method. Project phases: 1) the protein drug backbone production method (Leniobio), 2) the production of functional glycosylation enzymes (WUR), 3) immobilization and optimization of glycosylation enzymes towards the production of protein-based drugs (EnginZyme), 4) tests on a relevant scale. Due to challenges in phase 2, phase 3 was so delayed EnginZyme had to leave the consortium.